IN2014CN04935A - - Google Patents
Info
- Publication number
- IN2014CN04935A IN2014CN04935A IN4935CHN2014A IN2014CN04935A IN 2014CN04935 A IN2014CN04935 A IN 2014CN04935A IN 4935CHN2014 A IN4935CHN2014 A IN 4935CHN2014A IN 2014CN04935 A IN2014CN04935 A IN 2014CN04935A
- Authority
- IN
- India
- Prior art keywords
- tumor
- tissues
- probability
- invention describes
- gene
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 238000000018 DNA microarray Methods 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 238000011529 RT qPCR Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 238000003364 immunohistochemistry Methods 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 210000003296 saliva Anatomy 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161631291P | 2011-12-31 | 2011-12-31 | |
| PCT/IB2012/057844 WO2013098797A2 (en) | 2011-12-31 | 2012-12-31 | Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04935A true IN2014CN04935A (es) | 2015-09-18 |
Family
ID=48698732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4935CHN2014 IN2014CN04935A (es) | 2011-12-31 | 2012-12-31 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20140342946A1 (es) |
| IN (1) | IN2014CN04935A (es) |
| WO (1) | WO2013098797A2 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2294216A4 (en) | 2008-05-14 | 2011-11-23 | Dermtech Int | DIAGNOSIS OF MELANOMA AND SOLAR LENTIGO BY ANALYSIS OF NUCLEIC ACIDS |
| CN103525916B (zh) * | 2013-09-24 | 2016-06-15 | 浙江大学医学院附属第四医院 | 评估肝细胞癌预后的试剂盒及rffl的应用 |
| EP3294280A1 (en) | 2015-05-11 | 2018-03-21 | Yeda Research and Development Co., Ltd. | Citrin inhibitors for the treatment of cancer |
| WO2017004153A1 (en) * | 2015-06-29 | 2017-01-05 | The Broad Institute Inc. | Tumor and microenvironment gene expression, compositions of matter and methods of use thereof |
| KR101744397B1 (ko) * | 2015-07-07 | 2017-06-08 | 울산대학교 산학협력단 | 암 진단마커로서 Ｕｂａ６ 또는 Ｕｓｅ１의 용도 |
| WO2017095632A1 (en) * | 2015-11-30 | 2017-06-08 | Mayo Foundation For Medical Education And Research | Heatr1 as a marker for chemoresistance |
| CA2932910A1 (en) * | 2016-06-14 | 2017-12-14 | Entos Pharmaceuticals Inc. | Methods for diagnosing and treating metastatic cancer |
| CN106191295B (zh) * | 2016-08-30 | 2019-07-16 | 梁燕华 | Sharpin基因在制备诊断人皮肤肿瘤试剂中的用途 |
| US10487365B2 (en) | 2016-09-20 | 2019-11-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for detecting expression of lnc-FANCI-2 in cervical cells |
| EP3558368A4 (en) | 2016-12-23 | 2020-12-30 | MacroGenics, Inc. | ADAM9 BINDING MOLECULES AND THEIR METHODS FOR USE |
| PL3558391T3 (pl) | 2016-12-23 | 2022-05-16 | Immunogen, Inc. | Immunokoniugaty skierowane wobec białka adam9 i sposoby ich stosowania |
| MY192920A (en) * | 2017-03-15 | 2022-09-15 | Cancer Res Malaysia | Immunogenic peptide composition |
| CN107312843B (zh) * | 2017-07-06 | 2020-08-28 | 北京大学深圳医院（北京大学深圳临床医学院） | Krba1基因突变在制备乳腺癌检测试剂盒中的应用 |
| EP3689355A4 (en) * | 2017-07-28 | 2021-09-08 | Lemonex Inc. | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF LIVER CANCER |
| WO2019022586A2 (ko) * | 2017-07-28 | 2019-01-31 | 주식회사 레모넥스 | 간암의 예방 또는 치료용 약학적 조성물 |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| CN107621543B (zh) * | 2017-08-30 | 2019-10-01 | 福建师范大学 | Krba1蛋白在制备肝癌术后预后评估试剂盒中的应用、肝癌预后评估试剂盒及方法 |
| WO2019146841A1 (ko) * | 2018-01-25 | 2019-08-01 | 가톨릭대학교 산학협력단 | 간암의 진단 및 예후 예측용 바이오 마커 및 이의 용도 |
| KR102025005B1 (ko) * | 2018-01-25 | 2019-09-24 | 가톨릭대학교 산학협력단 | 전암성 병변에서 조기 간암을 진단 및 예측할 수 있는 바이오 마커 및 이의용도 |
| KR102270926B1 (ko) * | 2018-01-25 | 2021-06-30 | 주식회사 네오나 | Banf1, plod3 또는 sf3b4의 억제제를 유효성분으로 포함하는 간암의 예방 및 치료용 조성물 |
| EP3814378A1 (en) | 2018-06-26 | 2021-05-05 | ImmunoGen, Inc. | Immunoconjugates targeting adam9 and methods of use thereof |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN109722482A (zh) * | 2019-01-23 | 2019-05-07 | 宁波大学 | 分子标志物ska2在转移性肾透明细胞癌中的应用 |
| WO2020198229A1 (en) | 2019-03-26 | 2020-10-01 | Dermtech, Inc. | Novel gene classifiers and uses thereof in skin cancers |
| KR102203850B1 (ko) * | 2019-04-09 | 2021-01-18 | 사회복지법인 삼성생명공익재단 | 신경교종의 진단 또는 예후 예측용 조성물 및 이에 관한 정보를 제공하는 방법 |
| KR102042710B1 (ko) * | 2019-07-02 | 2019-11-08 | 의료법인 성광의료재단 | 면역체크 포인트와 관련된, 난소암 진단용 바이오마커 |
| CN111308074B (zh) * | 2019-12-12 | 2022-11-01 | 中山大学附属第三医院 | 检测肝细胞癌诊断标志物及筛查或辅助诊断产品中的应用 |
| KR20230124915A (ko) | 2020-12-23 | 2023-08-28 | 리제너론 파마슈티칼스 인코포레이티드 | 세포 사멸 유도 dffa 유사 이펙터 b(cideb) 억제제를 이용한 간 질환의 치료 |
| CN113238051A (zh) * | 2021-02-24 | 2021-08-10 | 深圳市人民医院 | 一种人源mob1蛋白的应用 |
| CN112980955A (zh) * | 2021-03-05 | 2021-06-18 | 南昌大学第二附属医院 | Emilin2作为胶质瘤替莫唑胺耐药检测、治疗及预后分子靶点的应用 |
| TW202302155A (zh) | 2021-03-08 | 2023-01-16 | 美商伊繆諾金公司 | 用於增加靶向ａｄａｍ９之免疫結合物治療癌症之功效的方法 |
| CN113917156A (zh) * | 2021-09-30 | 2022-01-11 | 复旦大学附属中山医院 | Hint2在制备治疗或诊断心力衰竭药物中的用途 |
| CN116312802B (zh) * | 2023-02-01 | 2023-11-28 | 中国医学科学院肿瘤医院 | 一种特征基因trim22用于制备调控乳腺癌相关基因表达的试剂的应用 |
| CN116617245B (zh) * | 2023-02-17 | 2023-11-10 | 新乡医学院 | Utp11抑制剂及其在肿瘤抑制中的用途 |
| CN117089621A (zh) * | 2023-09-28 | 2023-11-21 | 上海爱谱蒂康生物科技有限公司 | 生物标志物组合及其在预测结直肠癌疗效中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060281091A1 (en) * | 2003-07-07 | 2006-12-14 | Lavedan Christian N | Genes regulated in ovarian cancer a s prognostic and therapeutic targets |
| US20070172844A1 (en) * | 2005-09-28 | 2007-07-26 | University Of South Florida | Individualized cancer treatments |
| EP2370813A4 (en) * | 2008-12-04 | 2012-05-23 | Univ California | MATERIALS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF PROSTATE CANCER |
-
2012
- 2012-12-31 WO PCT/IB2012/057844 patent/WO2013098797A2/en active Application Filing
- 2012-12-31 US US14/368,801 patent/US20140342946A1/en not_active Abandoned
- 2012-12-31 IN IN4935CHN2014 patent/IN2014CN04935A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013098797A2 (en) | 2013-07-04 |
| US20140342946A1 (en) | 2014-11-20 |
| WO2013098797A3 (en) | 2013-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN04935A (es) | ||
| Dugger et al. | Drug development in the era of precision medicine | |
| Batagov et al. | Exosomes secreted by human cells transport largely mRNA fragments that are enriched in the 3′-untranslated regions | |
| Hahne et al. | Non-coding RNAs and resistance to anticancer drugs in gastrointestinal tumors | |
| Chen et al. | miR‑21‑5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3 | |
| Marsh et al. | Histones and their modifications in ovarian cancer–drivers of disease and therapeutic targets | |
| Menyhart et al. | A comprehensive outline of trastuzumab resistance biomarkers in HER2 overexpressing breast cancer | |
| EP3633041A3 (en) | Synthetic combinatorial aav capsid library for targeted gene therapy | |
| MX2021000210A (es) | Metodos y productos para transfeccion de celulas. | |
| WO2012103250A3 (en) | Colon cancer gene expression signatures and methods of use | |
| EP2569453A4 (en) | Nucleic Acid ISOLATION METHOD | |
| WO2011122857A3 (ko) | 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트 | |
| Arrighetti et al. | Mirnas as therapeutic tools and biomarkers for prostate cancer | |
| US20200390873A1 (en) | Neoantigen immunotherapies | |
| Alderman et al. | The anti-melanoma activity and oncogenic targets of hsa-miR-15a-5p | |
| MX2013008252A (es) | Firma de pronostico para la recurrencia de cancer colorrectal. | |
| Fujiwara et al. | MicroRNAs in soft tissue sarcomas: overview of the accumulating evidence and importance as novel biomarkers | |
| Kunz et al. | MicroRNA-21 versus microRNA-34: lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact | |
| Gao et al. | LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer | |
| WO2012131670A3 (en) | Methods for lung cancer clasification | |
| Bertoni et al. | Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangioma | |
| Huang et al. | Effect of miR‑146a‑5p on tumor growth in NSCLC using chick chorioallantoic membrane assay and bioinformatics investigation | |
| Lu et al. | Transcriptome sequencing investigated the tumor-related factors changes after T. gondii infection | |
| SG179129A1 (en) | Method for identifying whether a patient will be responder or not to immunotherapy | |
| Shin et al. | MUDENG expression profiling in cohorts and brain tumor biospecimens to evaluate its role in cancer |